Hantz Financial Services Inc. Acquires 3,554 Shares of Illumina, Inc. $ILMN

Hantz Financial Services Inc. grew its position in Illumina, Inc. (NASDAQ:ILMN) by 100.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,087 shares of the life sciences company’s stock after purchasing an additional 3,554 shares during the quarter. Hantz Financial Services Inc.’s holdings in Illumina were worth $930,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB grew its stake in shares of Illumina by 7.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after acquiring an additional 79 shares during the last quarter. HighPoint Advisor Group LLC lifted its holdings in shares of Illumina by 3.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after acquiring an additional 80 shares during the period. Assetmark Inc. lifted its holdings in shares of Illumina by 10.2% during the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after acquiring an additional 96 shares during the period. Venturi Wealth Management LLC boosted its stake in shares of Illumina by 4.2% in the 4th quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock valued at $323,000 after purchasing an additional 99 shares in the last quarter. Finally, Banque Cantonale Vaudoise boosted its stake in shares of Illumina by 1.5% in the 4th quarter. Banque Cantonale Vaudoise now owns 7,071 shares of the life sciences company’s stock valued at $927,000 after purchasing an additional 107 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ILMN shares. Wall Street Zen downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Barclays boosted their price objective on Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a report on Friday, May 1st. Canaccord Genuity Group cut their price target on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Royal Bank Of Canada initiated coverage on shares of Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target on the stock. Finally, Robert W. Baird set a $137.00 target price on Illumina in a research note on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Illumina presently has a consensus rating of “Hold” and a consensus target price of $137.75.

Insider Transactions at Illumina

In other news, Director Keith A. Meister sold 104,393 shares of Illumina stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the sale, the director directly owned 3,500,048 shares of the company’s stock, valued at approximately $508,696,976.32. This trade represents a 2.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Christensen Jakob Wedel sold 700 shares of Illumina stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the transaction, the senior vice president directly owned 15,056 shares in the company, valued at approximately $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 330,160 shares of company stock worth $48,028,308 over the last three months. Insiders own 2.90% of the company’s stock.

Illumina Stock Up 3.4%

ILMN opened at $150.17 on Thursday. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 1-year low of $78.79 and a 1-year high of $155.53. The stock has a market cap of $22.72 billion, a PE ratio of 27.30, a price-to-earnings-growth ratio of 2.40 and a beta of 1.42. The stock’s fifty day simple moving average is $132.17 and its 200 day simple moving average is $131.55.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the business earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts expect that Illumina, Inc. will post 5.2 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.